DNA X, Inc.
corporate_fare Company Profile
DNA X, Inc. (NASDAQ:SONM) is a publicly traded company in the Manufacturing sector. Wiseek has independently scored 17 items for SONM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-31, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for SONM spans 8-K, 10-Q, 8-K/A, 10-K.
Recent high-impact activity:
- DNA X Regains Nasdaq Compliance, Avoids Delisting
- DNA X Flags Material Weakness and Going Concern in Q2 10-Q
- DNA X Completes $2.5M Series B Sale, Projects Nasdaq Equity Compliance
- DNA X Amends 8-K: $5.6M Series B Preferred Financing Lifts Pro Forma Equity Above Nasdaq Minimum
- DNA X Secures $8.1M Financing via Preferred Stock and Debt Conversion from Insider
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 9,830 shares in SONM as of the October 30, 2026 settlement, a 9.1% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 18.5% of SONM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for SONM, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.
Secured $8.1 Million Financing · Insider-Led Capital Infusion
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →